NCT05179213 is a Phase 2 clinical trial of Azacitidine in Angioimmunoblastic T-cell Lymphoma, sponsored by Peking Union Medical College Hospital.

Who is sponsoring NCT05179213?

NCT05179213 is sponsored by Peking Union Medical College Hospital.

What drugs are being tested in NCT05179213?

Interventions in NCT05179213: Azacitidine, Chidamide.

What condition does NCT05179213 study?

NCT05179213 studies Angioimmunoblastic T-cell Lymphoma.

Is NCT05179213 still recruiting?

NCT05179213 is currently status unknown. Last updated 5 January 2022.

Last reviewed 2022-01-05 · How we verify

NCT05179213

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma

Status unknown Phase 2 Last updated 5 January 2022

What this trial tests

Phase 2 trial testing Azacitidine in Angioimmunoblastic T-cell Lymphoma in 20 participants. Status unknown.

Timeline

1 January 2022

Primary endpoint
1 January 2024

1 May 2024

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 January 2022
Primary completion	1 January 2024
Estimated completion	1 May 2024
Sites	1 location across China

Drugs / interventions tested

Azacitidine (azacitidine) — full drug profile →
Chidamide — full drug profile →

Conditions studied

Angioimmunoblastic T-cell Lymphoma — all drugs for Angioimmunoblastic T-cell Lymphoma →

Sponsor

Peking Union Medical College Hospital

Who can join

18 and older, any sex, with Angioimmunoblastic T-cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter prospective single arm phase II study. The purpose of this study is to evaluate the safety and efficiency of azacytidine combined with chidamide in the treatment of relapsed/refractory angioimmunoblastic T-cell lymphoma.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.
Zhao A, Zhou H, Yang J, Li M, et al · · 2023 · cited 81× · PMID 36797244 · DOI 10.1038/s41392-023-01342-6
Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment.
Sun Y, Hong JH, Ning Z, Pan D, et al · · 2022 · cited 58× · PMID 36120308 · DOI 10.3389/fphar.2022.932914
The Status and Prospects of Epigenetics in the Treatment of Lymphoma.
Liu J, Li JN, Wu H, Liu P. · · 2022 · cited 10× · PMID 35463343 · DOI 10.3389/fonc.2022.874645

Verify or expand the search:

Other trials of Azacitidine

Trials testing the same drug.

NCT07508982 — Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML · Phase 1, PHASE2 · not yet recruiting
NCT05554419 — Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Tr · Phase 2 · not yet recruiting
NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting
NCT07469046 — VAH vs VA in Newly Diagnosed Elderly AML · Phase 3 · not yet recruiting
NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting

Other recruiting trials for Angioimmunoblastic T-cell Lymphoma

Currently open trials in the same condition.

NCT07388563 — Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma · Phase 1 · recruiting
NCT07055477 — A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T- · Phase 1 · recruiting
NCT04234048 — Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma · Phase 1 · recruiting
NCT05377827 — Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU- · Phase 1 · active not recruiting
NCT05978141 — A Registry for People With T-cell Lymphoma · recruiting

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05179213 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 5 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05179213.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing